A greater level of anti-glycan antibody production may partly explain the association between COVID-19 vaccination and IgA nephropathy, given that anti-glycan antibodies cross-react with poorly galactosylated IgA1 and that mucosal immune responses are not stimulated following COVID-19 vaccination [12,38,39]. The gene discussed is IGHA1; the disease is COVID-19.